Last reviewed · How we verify
NCT06741358: GLI-PPPD
Using Glialia for Treating Persistent Perceptual Postural Dizziness
Phase 4 trial testing Glialia in Persistent Postural Perceptual Dizziness in 30 participants. Currently enrolling.
10 October 2025
Quick facts
| Lead sponsor | I.R.C.C.S. Fondazione Santa Lucia |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 21 December 2024 |
| Primary completion | 10 October 2025 |
| Estimated completion | 10 October 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Glialia
- Placebo
- Control
Conditions studied
- Persistent Postural Perceptual Dizziness — all drugs for Persistent Postural Perceptual Dizziness →
Sponsor
I.R.C.C.S. Fondazione Santa Lucia — full company profile →
Who can join
Adults 18 to 65, any sex, with Persistent Postural Perceptual Dizziness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This pilot study will involve 30 participants recruited from the Santa Lucia Foundation IRCCS, including 20 patients diagnosed with Persistent Perceptual Postural Dizziness (PPPD), and might or might not have previously contracted Sars Cov2 infection. They who will be randomly assigned to receive either the Glialia supplement or placebo. Additionally, 10 control participants who have recovered from COVID-19 will receive Glialia to help assess the influence of previous COVID-19 infection on neuroinflammation levels. The study aims to compare baseline neuroinflammation levels between PPPD patients and controls, measure changes in neuroinflammation in all groups after treatment and to determine if the reduction in neuroinflammation is more significant in the Glialia group compared to the placebo group. The trial will be conducted in a triple-blind manner, ensuring that neither participants nor researchers know the treatment assignments. Each participant will receive sachets to be taken daily for 60 days, with the study providing both the Glialia supplement and placebo at no cost.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06741358
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other I.R.C.C.S. Fondazione Santa Lucia trials
Trials by the same sponsor.
- NCT07257679 — Gentle Touch for Post-Mastectomy Lymphedema · Phase 4 · recruiting
- NCT07254377 — Design and Validation of Innovative Strategies Based on Dual-Task Approach · NA · active not recruiting
- NCT06420271 — Effects of Cerebellar tACS-iTBS in Ataxia · NA · recruiting
- NCT06911671 — EMG Control Assistance Virtual Reality Interface Coupled With Cerebellar-iTBS for Arm Recovery After Stroke (ERICA) · NA · recruiting
- NCT07075770 — Novel Personalized Non Invasive Combined Magnetic and Electrical Stimulation of the DMN in Mild AD Patients · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06741358 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by I.R.C.C.S. Fondazione Santa Lucia
- Last refreshed: 20 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06741358.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing